The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)
Abstract
Multidrug resistance (MDR) remains one of the major impediments for efficacious cancer chemotherapy. Increased efflux of multiple chemotherapeutic drugs by transmembrane ATP‐binding cassette (ABC) transporter superfamily is considered one of the primary causes for cancer MDR, in which the role of P‐glycoprotein (P‐gp/ABCB1) has been most well‐established. The clinical co‐administration of P‐gp drug efflux inhibitors, in combination with anticancer drugs which are P‐gp transport substrates, was considered to be a treatment modality to surmount MDR in anticancer therapy by blocking P‐gp‐mediated multidrug efflux. Extensive attempts have been carried out to screen for sets of nontoxic, selective, and efficacious P‐gp efflux inhibitors. In this review, we highlight the recent achievements in drug design, characterization, structure–activity relationship (SAR) studies, and mechanisms of action of the newly synthetic, potent small molecules P‐gp inhibitors in the past 5 years. The development of P‐gp inhibitors will increase our knowledge of the mechanisms and functions of P‐gp‐mediated drug efflux which will benefit drug discovery and clinical cancer therapeutics where P‐gp transporter overexpression has been implicated in MDR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wang, Y., Patel, B. A., Anreddy, N., Zhang, Y., Zhang, G.-N., Alqahtani, S., Singh, S., Shukla, S., Kaddoumi, A., Ambudkar, S. V., et al. (2017) · Scientific Reports · doi:10.1038/srep42106 · Cited by 16
Self-citationRetractedCohen, A. J., Brauer, M., Burnett, R., Anderson, H. R., Frostad, J., Estep, K., Balakrishnan, K., Brunekreef, B., Dandona, L., Dandona, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30505-6 · Cited by 6,583
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
Wolber, G., & Langer, T. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049885e · Cited by 1,954
Chen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866
Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F., & Wolff, J. A. (1948) · New England Journal of Medicine · doi:10.1056/nejm194806032382301 · Cited by 1,806
Structure, Function, and Evolution of Bacterial ATP-Binding Cassette Systems
Davidson, A. L., Dassa, E., Orelle, C., & Chen, J. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-07 · Cited by 1,420
Twenty years on: the impact of fragments on drug discovery
Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W., & Jhoti, H. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.109 · Cited by 1,000
Medicinal attributes of 1,2,3-triazoles: Current developments
Dheer, D., Singh, V., & Shankar, R. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.01.010 · Cited by 873
Research works printed but not linked: 47
- Seton‐Rogers S, 2016, Resistance: following different paths, Nat Rev Cancer, 16, 128, 10.1038/nrc.2016.23 · doi:10.1038/nrc.2016.23
- 10.1016/j.drup.2012.03.001 · doi:10.1016/j.drup.2012.03.001
- 10.1002/wcms.1316 · doi:10.1002/wcms.1316
- 10.1124/mol.58.3.624 · doi:10.1124/mol.58.3.624 · Paper page
- 10.1016/j.lfs.2018.10.048 · doi:10.1016/j.lfs.2018.10.048
- 10.2174/1381612822666160804093852 · doi:10.2174/1381612822666160804093852
- 10.1016/j.ejmech.2014.10.082 · doi:10.1016/j.ejmech.2014.10.082
- 10.1002/cmdc.201500538 · doi:10.1002/cmdc.201500538
- 10.1021/acs.jmedchem.6b00252 · doi:10.1021/acs.jmedchem.6b00252
- 10.1016/j.bmc.2016.04.055 · doi:10.1016/j.bmc.2016.04.055
- 10.1002/cmdc.201402463 · doi:10.1002/cmdc.201402463
- 10.1139/cjpp-2016-0518 · doi:10.1139/cjpp-2016-0518
- 10.1016/j.bmc.2016.03.065 · doi:10.1016/j.bmc.2016.03.065
- 10.1039/C6RA02405J · doi:10.1039/c6ra02405j
- 10.1016/j.bmc.2018.03.045 · doi:10.1016/j.bmc.2018.03.045
- 10.1111/cbdd.13338 · doi:10.1111/cbdd.13338
- 10.1016/j.bioorg.2019.01.039 · doi:10.1016/j.bioorg.2019.01.039
- 10.1021/jacs.6b11188 · doi:10.1021/jacs.6b11188
- 10.1021/acs.joc.8b00322 · doi:10.1021/acs.joc.8b00322
- 10.1021/acs.jmedchem.0c00337 · doi:10.1021/acs.jmedchem.0c00337
- 10.1016/j.ejmech.2018.04.012 · doi:10.1016/j.ejmech.2018.04.012
- 10.1080/14756366.2020.1747449 · doi:10.1080/14756366.2020.1747449
- 10.1016/j.ejmech.2018.01.092 · doi:10.1016/j.ejmech.2018.01.092
- 10.1021/jm9810194 · doi:10.1021/jm9810194
- 10.1021/jm050542x · doi:10.1021/jm050542x
- 10.1021/jm0614432 · doi:10.1021/jm0614432
- 10.1002/cmdc.201500143 · doi:10.1002/cmdc.201500143
- 10.1021/jm400930e · doi:10.1021/jm400930e
- 10.1016/j.bmc.2015.07.027 · doi:10.1016/j.bmc.2015.07.027
- 10.1016/j.ejmech.2016.09.070 · doi:10.1016/j.ejmech.2016.09.070
- Feng S‐L, 2020, Nobiletin potentiates paclitaxel anticancer efficacy in A549/T xenograft model: pharmacokinetic and pharmacological study, Phytomedicine, 67
- 10.1515/hc-2016-0034 · doi:10.1515/hc-2016-0034
- 10.1016/j.ejphar.2014.10.058 · doi:10.1016/j.ejphar.2014.10.058
- 10.1039/C4MD00506F · doi:10.1039/c4md00506f
- 10.1016/j.bmcl.2015.05.018 · doi:10.1016/j.bmcl.2015.05.018
- 10.1016/j.bmc.2015.05.016 · doi:10.1016/j.bmc.2015.05.016
- 10.1021/mp500770e · doi:10.1021/mp500770e
- 10.1016/j.ejmech.2016.08.044 · doi:10.1016/j.ejmech.2016.08.044
- 10.1016/j.ejmech.2014.10.044 · doi:10.1016/j.ejmech.2014.10.044
- 10.1021/acs.joc.7b02012 · doi:10.1021/acs.joc.7b02012
- 10.1016/j.ejmech.2018.01.019 · doi:10.1016/j.ejmech.2018.01.019
- 10.1039/C5RA19857G · doi:10.1039/c5ra19857g
- 10.1016/j.ymeth.2014.12.012 · doi:10.1016/j.ymeth.2014.12.012
- 10.3390/molecules24091661 · doi:10.3390/molecules24091661
- 10.1016/j.ejmech.2016.01.034 · doi:10.1016/j.ejmech.2016.01.034
- 10.1016/j.ijpharm.2016.02.022 · doi:10.1016/j.ijpharm.2016.02.022
- 10.1016/j.ijantimicag.2014.10.023 · doi:10.1016/j.ijantimicag.2014.10.023
Cited by
Therapeutic strategies to overcome taxane resistance in cancer
Das, T., Anand, U., Pandey, S. K., Ashby, C. R., Assaraf, Y. G., Chen, Z.-S., & Dey, A. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100754 · Cited by 253
Self-citationHanssen, K. M., Haber, M., & Fletcher, J. I. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100795 · Cited by 102
The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials
Peng, J., Yang, S., Ng, C. S. H., & Chen, G. G. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108333 · Cited by 21
Ji, Q.-L., Zeng, Y., Zhou, H., Wang, Q.-B., Zhou, R.-Y., Zhang, J.-J., & Wang, X. (2026) · Scientific reports · doi:10.1038/s41598-026-49617-6 · Cited by 1
“P-glycoprotein (P-gp) is a typical membrane-associated pump that actively transports drugs out of cells 15 .”
Metadata
- Authors
- Zhang, H., Xu, H., Ashby, C. R., Assaraf, Y. G., Chen, Z., & Liu, H.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2020-10-12
- Volume
- 41
- Issue
- 1
- Pages
- 525-555
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W3091980736
- Cited by
- 270
- References
- 117
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp). https://app.cochat.ai/papers/10.1002/med.21739
- The paper
- Zhang, H., Xu, H., Ashby, C. R., Assaraf, Y. G., Chen, Z., & Liu, H. (2021). Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp). Medicinal Research Reviews. https://doi.org/10.1002/med.21739
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.